glp-1 als Science's 2023 Breakthrough: GLP-1R Agonists The multifaceted role of GLP-1

Large clinical trials running for several years show that GLP-1s not only improve sugar and weight but also reduce heart and kidney risks in many people with type 2 diabetes, with an acceptable safety profile when monitored

You were on a therapeutic dose of semaglutide, and now you are on a sub-therapeutic starting dose of tirzepatide

Why Patient Behavior Is Reshaping the GLP-1 Landscape In the fast-shifting world of obesity treatment, patient behavior is proving to be a powerful force, one that can make or break the success of even the most promising therapies

Elkind-Hirsch et al

Pocai A, Carrington PE, Adams JR et al (2009) Glucagon-like peptide-1/glucagon receptor dual agonism reverses obesity in mice

The average medical school provides limited nutrition education throughout a students four years, and nutrition-related competencies are often absent from most medical specialties in graduate medical education